News and

Curesponse shows applicability with next generation immuno-oncology drugs

Curesponse’s poster presented at the recent ESMO Immuno-Oncology Congress in Geneva showed the cResponse™ platform can be applied for the modeling and evaluation of immune modulating drugs in cancer tissue.
The cResponse™ assay maintains the high viability of human cancer, uniquely preserving the 3D architecture together with its microenvironment, including immune cells for sufficient time to assess immuno-oncology response. The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.


Want to know more?

Contact Us